Abpro Holdings (ABPO) Liabilities and Shareholders Equity (2021 - 2026)
Abpro Holdings' (ABPO) quarterly Liabilities and Shareholders Equity came in at $6.9 million in Q1 2026, up 145.44% YoY from $2.8 million in Q1 2025, and up 545.81% on a QoQ basis from $1.1 million in Q4 2025.
Abpro Holdings (ABPO) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends
Abpro Holdings (ABPO) has 6 years of Liabilities and Shareholders Equity data on file, last reported at $6.9 million in Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 145.44% year-over-year to $6.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.1 million (down 43.5% YoY) and the FY2025 annual result came in at $1.1 million, down 77.19% from the prior year.
- Liabilities and Shareholders Equity climbed to $6.9 million in Q1 2026, from $1.1 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $313.6 million in Q1 2023 to a low of $1.1 million in Q4 2025.
- A 5-year average of $98.2 million and a median of $7.9 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 85839.33% — and 2023, when it tumbled 98.92%.
- Tracing ABPO's Liabilities and Shareholders Equity over 5 years: stood at $310.6 million in 2022, then plunged by 98.92% to $3.4 million in 2023, then jumped by 38.93% to $4.7 million in 2024, then slumped by 77.19% to $1.1 million in 2025, then soared by 545.81% to $6.9 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $6.9 million (Q1 2026), $1.1 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Abpro Holdings | 1.14 Mn | 1.14 Mn | - | 5.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.87 Mn |
| Dec 31, 2025 | 1.06 Mn |
| Sep 30, 2025 | 1.70 Mn |
| Jun 30, 2025 | 3.48 Mn |
| Mar 31, 2025 | 2.80 Mn |
| Dec 31, 2024 | 4.66 Mn |
| Sep 30, 2024 | 7.86 Mn |
| Jun 30, 2024 | 7.90 Mn |
| Mar 31, 2024 | 7.53 Mn |
| Dec 31, 2023 | 3.36 Mn |
| Sep 30, 2023 | 37.52 Mn |
| Jun 30, 2023 | 38.44 Mn |
| Mar 31, 2023 | 313.65 Mn |
| Dec 31, 2022 | 310.56 Mn |
| Sep 30, 2022 | 308.23 Mn |
| Jun 30, 2022 | 306.98 Mn |
| Mar 31, 2022 | 306.90 Mn |
| Dec 31, 2021 | 361,372.00 |